Introduction: Staphylococcal infections can cause significant morbidity in patients undergoing dialysis. This study evaluated the effects of HIV infection on nasal carriage of Staphylococcus aureus, staphylococcal peritonitis, and catheter infection rates in patients with end-stage renal failure managed with continuous ambulatory peritoneal dialysis (CAPD). Methods: Sixty HIV-positive and 59 HIV-negative CAPD patients were enrolled and followed up for up to 18 months. S. aureus nasal carriage (detected by nasal swab culture), Staphylococcal peritonitis (diagnosed by clinical presentation, and CAPD effluent Staphylococcal culture and white blood cell count !100 cells/mL), and catheter infections (including exit site and tunnel infections) were assessed monthly. Results: At 18 months, S. aureus nasal carriage rates were 43.3% and 30.5% (p ¼ 0.147) and the methicillin-resistant S. aureus (MRSA) nasal carriage rates were 31.7% and 13.6% (p ¼ 0.018) for the HIV-positive and HIV-negative cohorts, respectively. The HIV-positive cohort was associated with increased hazards for staphylococcal peritonitis, (adjusted hazard ratio [AHR] 2.85, 95% confidence interval [CI] 1.19-6.84, p ¼ 0.019) due to increased coagulase-negative staphylococcal (CNS) peritonitis rate in the HIV-positive cohort compared with the HIV-negative cohort (0.435 vs. 0.089 episodes/person-years; AHR 7.64, CI 2.18-26.82, p ¼ 0.001). On multivariable analysis, CD4þ cell count <200 cells/mL, diabetes, and S. aureus nasal carriage were found to be independent predictors of S. aureus peritonitis. Conclusions: These findings suggest that HIV infection may be a risk factor for MRSA nasal colonization and may increase the risks of CNS peritonitis, while a CD4þ cell count <200 cells/mL and S. aureus nasal carriage may be important predictors of S. aureus peritonitis.
Introduction
Infection is a major challenge in patients with end-stage renal failure who are managed with continuous ambulatory peritoneal dialysis (CAPD), and it is an important source of morbidity and technique failure. Gram-positive bacteria, most notably coagulase-negative staphylococci (CNS) and Staphylococcus aureus, frequently cause CAPD-associated peritonitis [1] [2] [3] . Peritonitis caused by CNS infection tends to follow a benign clinical course that is easily treatable, while S. aureus peritonitis can be complicated with relapses and the need for catheter removal, particularly if it is associated with exit site or tunnel infections. An important risk factor for CAPD-associated exit site infections and peritonitis is S. aureus nasal carriage [4] [5] [6] . An association between HIV infection and increased rates of S. aureus nasal colonization in the general population has been reported, and increased likelihood of colonization has been suggested in the advanced stages of HIV infection [7, 8] .
Infective complications in HIV-positive patients on dialysis can cause significant morbidity and mortality, and they can result in the need to transfer to hemodialysis, which gives rise to greater cost burdens to health budgets. In poorly resourced regions, such as subSaharan Africa, where HIV is prevalent, but access to renal replacement therapy (RRT) is limited, CAPD can represent a cost-effective option. Africa has been estimated to have the lowest RRT access at between 9% and 16%, reflecting a significant unmet need [9] . Indeed, CAPD can be implemented with relative ease and without the need for complex equipment, and it is well suited for areas that are remote or have limited dialysis facilities [10] [11] [12] . This study aimed to evaluate the effects of HIV infection on S. aureus nasal carriage, staphylococcal peritonitis, and catheter infection rates in patients with end-stage renal disease (ESRD) who were managed with CAPD.
Materials and methods

Study population
This prospective sub-cohort of 129 patients was drawn from a 140-patient cohort recruited from King Edward VIII Hospital and Inkosi Albert Luthuli Central Hospital (IALCH), Durban, South Africa, which has been described previously [13, 14] . Consecutive patients aged 18 to 60 years who required dialysis and had newly inserted double-cuffed coiled Tenckhoff catheters were recruited between September 2012 and February 2015 stopping enrollment when each cohort had 70 participants. Sixty HIV-positive and 59 HIV-negative patients who had at least one nasal swab sample taken during follow-up were included in this sub-study. The study protocol was approved by the University of KwaZuluNatal Biomedical Research Ethics Committee (BE 187/ 11), and informed consent was obtained from the patients before enrollment. The status of HIV infection was determined by two 4th generation HIV enzymelinked immunosorbent assays performed by the South African National Health Laboratory Service (NHLS) before enrollment; screening for HIV was performed using a HIV Ag/Ab Combo (CHIV) assay (ADVIA CentaurV R XP, Siemens Healthcare Diagnostics, Tarrytown, NY) and confirmation was done using HIV Combi and HIV Combi PT assays (Cobas e601, Roche Diagnostics, Mannheim, Germany). Antiretroviral therapy (ART) was left to the discretion of the local clinic.
Y-sets, twin-bag systems, and conventional peritoneal dialysis (PD) solutions (DianealV R 1.5%, 2.5%, or 4.25% dextrose, icodextrin, or amino acid-based solutions; Baxter Healthcare, Deerfield, IL) were used in all CAPD patients. They generally performed four exchanges per day. All patients received approximately 40 h of practical and theoretical CAPD training in groups and individualized sessions conducted by the same nursing team of two senior nurses working together. A prophylactic intravenous antibiotic was administered to all patients prior to PD catheter insertion. Patients were prescribed 4% chlorhexidine Surgiscrub soap for hand washing and chlorhexidine 0.5% in ethanol 70% solution for hand rubs between hand washing. They were directed to use water and medicated soaps of their choice for exit site care.
Enrollment and follow-up
The patients' demographic, clinical, and biochemical data were documented on enrollment. The patients were followed up monthly at a central renal clinic in IALCH for 18 months or until the endpoints of catheter removal and subsequent transfer to hemodialysis or death. At each follow-up assessment, nasal swabs were taken, phlebotomy was performed for biochemical tests, and the details of infective complications and hospital admissions in the intervening periods were recorded on predefined questionnaires. Full blood counts were performed, and the serum concentrations of C-reactive protein (CRP), urea, creatinine, electrolytes, and albumin were measured at NHLS, and the results were periodically retrieved from the IALCH's electronic results database.
Microbiology
Swabbing of the anterior nasal vestibules with sterile swabs (Amies Agar Gel-No Charcoal Transport System; Copan Italia SpA, Brescia, Italy) was performed monthly by a research nurse, and the swabs were transported to the laboratory for processing. Colistin-nalidixic agar and mannitol salt agar media were used for the cultures. The CAPD nurse took PD effluent specimens for white blood cell (WBC) counts and culture when the patients' clinical presentations suggested peritonitis, and they were transported to the NHLS microbiology department in sterile specimen bottles for processing. The PD effluent WBC counts were determined using a 40Â microscope objective lens. The culturing was done on chocolate, blood agar, and brain-heart infusion broth. A VitekV R 2 system (bioM erieux, France) was used for identification and antibiotic susceptibility testing of the nasal swab and PD effluent specimens.
Definitions
A peritonitis episode was defined as a clinical presentation with a cloudy effluent or abdominal pain associated with a PD effluent WBC count of >100 cells/mL or a positive culture. All patients were treated for at least 2 weeks, and they initially received intraperitoneal vancomycin and amikacin empirically, with further therapy modified according to the culture results. Episodes with culture-confirmed Staphylococcus growth and the date of presentation, information about whether the patient was treated as an inpatient or outpatient, and the presenting PD WBC counts were included in this analysis. The infection rates were calculated as the total number of infectious episodes with an organism during the follow-up period divided by the dialysis-years' time at risk, and they were expressed as the number of episodes per year [15] .
Exit site infections were diagnosed clinically and defined based on the presence of purulent drainage, with or without skin erythema, at the catheterepidermal interface. Tunnel infections were diagnosed clinically or using sonographic studies, and they were defined based on the presence of erythema, edema, or tenderness over the subcutaneous pathway [15] . Both infection types were referred to as catheter infections.
The participants were classified as S. aureus nasal carriers if at least one culture from the monthly nasal swabs was positive for S. aureus, and they were classified as non-carriers if none of the cultures from the monthly nasal swabs was positive for S. aureus during follow-up. The S. aureus nasal carriers were further classified as intermittent S. aureus carriers if only one nasal culture was positive for S. aureus during follow-up or as persistent carriers if more than one monthly nasal culture was positive for S. aureus.
Mupirocin exposure
Exposure to mupirocin during the study was determined through evaluation of the electronic hospital database at the end of the study period for instances where mupirocin was dispensed during each patient's follow-up period. The date of the first documented prescription of mupirocin and the number of months prescribed were recorded for individual patients.
Statistical analysis
The continuous variables were expressed as the mean-± standard deviation (SD) or median and the interquartile range (IQR), and they were compared using Cox proportional hazard analysis was used to estimate the associations between HIV infection and the peritonitis outcome events due to Staphylococcus species, S. aureus, and CNS, respectively. Multivariable Cox proportional hazard analysis was used to identify independent predictors of each Staphylococcal peritonitis event type. The covariates included in the all Cox models for the peritonitis outcome variables were age, race, gender, smoking, diabetes, BMI, baseline serum albumin, baseline CD4þ cell count, Tenckhoff catheter insertion parameters (site and method), mupirocin exposure, type of primary residence, highest education level, and employment. In the Cox model for Staphylococcus species peritonitis, further covariates of Staphylococcus species nasal carriage and catheter infection were added. In the Cox model for S. aureus peritonitis, additional covariates of the S. aureus nasal carriage and catheter infection were included. In the Cox model for CNS peritonitis, additional covariates of CNS nasal carriage and Staphylococcus species catheter infection were included. All the analyses were performed using Stata, version 15.0 (StataCorp LP, College Station, TX), and the significance level was set at p < 0.05.
Results
Patients' characteristics
The study population of 119 CAPD patients included 59 HIV-negative and 60 HIV-positive patients with a median age of 39 years (IQR: 29-49 years) and 34 years (IQR: 30-41.5 years), respectively, (p ¼ 0.207). Fifty-two percent of the HIV-positive patients were either newly diagnosed with HIV or had recently been started on ART, less than six months before Tenckhoff catheter insertion. Sixty percent of the HIV-positive patients had a suppressed viral load of <150 copies/mL, which was the hospital laboratory assay's limit at the time of enrollment. While the median baseline viral load was 4 229.5 copies/mL (IQR: 817-88,294.5 copies/mL) for the patients with detectable viral loads, the median fell below the detectable limit (IQR: <150-2284.5 copies/ mL) when the patients with undetectable viral loads were included. The characteristics of the study population are outlined in Table 1 .
Study drop out
After 18 months, 64.4% (38 of 59) of the HIV-negative patients and 33.3% (20 of 60) of the HIV-positive patients were alive with patent catheters (p ¼ 0.001). Twenty-two percent (13 of 59) of the HIV-negative 
Median, copies/mL (IQR) 4 229.5 (817-88 294.5) Suppressed (<150 copies/mL), n (%) 36 (60.0) 150-1000 copies/mL, n (%) 7 (11.7) >1000 copies/mL, n (%) 17 (28.3) ART history at enrollment <6 months, n (%) 31 (51.7) 6-12 months, n (%) patients and 25.0% (15 of 60) of the HIV-positive patients (p ¼ 0.703) had their Tenckhoff catheters removed because of malfunctions or infective complications, and 10.2% (6 of 59) of the HIV-negative patients and 36.7% (22 of 60) of the HIV-positive patients had died (p ¼ 0.001). Forty-eight percent (13 of 27) of HIVpositive patients with baseline CD4 counts <350 cells/ mL died, and 27.3% (9/33) of HIV-positive patients with CD4 counts !350 cells/mL died, both significantly higher than the HIV-negative proportion (p < 0.001). Two HIV-negative and three HIV-positive patients were lost to follow-up due to live related renal transplantation, improved renal functions, or opted for private hemodialysis (Supporting Information Table 1 ).
Staphylococcal nasal carriage
Thirty percent (18 of 59) of the HIV-negative patients and 43.3% (26 of 60) of the HIV-positive patients had detectable S. aureus in the nares (p ¼ 0.147) ( (Tables 4 and 5 ).
Coagulase-negative staphylococci peritonitis rates were 0.089 episodes/person-years in the HIV-negative S. aureus peritonitis rates were 0.129 episodes/person-years in the HIV-negative cohort and 0.136 episodes/person-years in the HIV-positive cohort (RR 1.05, CI 0.39-2.82, p ¼ 0.920). HIV was not significantly associated with S. aureus peritonitis events on both univariate 27 , p ¼ 0.008), male gender, S. aureus nasal carriage, and diabetes were found to be independent predictors of S. aureus peritonitis.
Exit site and tunnel infections
Ten catheter infection episodes occurred in the HIVnegative cohort, and 14 catheter infection episodes occurred in the HIV-positive cohort in 15.2% (9 of 59) and 18.3% (11 of 60) of the patients, respectively. S. Table 4 ). The S. aureus catheter infection rates were 0.199 episodes/person-years for the S. aureus nasal carriers and 0.056 episodes/person-years for the non-carriers (RR 3.57, CI 1.10-11.59, p ¼ 0.024).
Mupirocin exposure
Eighty-six percent (51 of 59) of the HIV-negative cohort had mupirocin ointment prescribed for exit site application compared to 60.0% (36 of 60) of the HIV-positive cohort (p ¼ 0.001), due to the earlier recruitment of a greater proportion of HIV-negative patients when .00 a Cox model for Staphylococci species peritonitis outcome included variables of HIV, age, race, gender, smoking, diabetes, body mass index, baseline serum albumin, primary residence, highest education level, employment, baseline CD4 count, Tenckhoff catheter insertion site, Tenckhoff catheter insertion method (laparoscopic vs. percutaneous), staphylococci species nasal carriage, staphylococci species catheter infection, and exposure to topical mupirocin at exit site. b One patient record excluded in analysis due to missing data on primary residence, education, and employment. cCox model for coagulase-negative staphylococci peritonitis outcome included variables of HIV, age, race, gender, smoking, diabetes, body mass index, baseline serum albumin, primary residence, highest education level, employment, baseline CD4 count, Tenckhoff catheter insertion site, Tenckhoff catheter insertion method (laparoscopic vs. percutaneous), coagulase-negative staphylococci nasal carriage, staphylococci catheter infection, and exposure to topical mupirocin at exit site. d Cox model for Staphylococcus aureus peritonitis outcome included variables of HIV, age, race, gender, smoking, diabetes, body mass index, baseline serum albumin, primary residence, highest education level, employment, baseline CD4 count, Tenckhoff catheter insertion site, Tenckhoff catheter insertion method (laparoscopic vs. percutaneous), Staphylococcus aureus nasal carriage, Staphylococcus aureus catheter infection, and exposure to topical mupirocin at exit site. BMI: body mass index; CI: confidence interval; CD: cluster of differentiation; HR: hazard ratio; HIV: human immunodeficiency virus.
hospital policy favored routine mupirocin exit site prophylaxis. Furthermore, mupirocin ointment was prescribed for a median 5 (2-9) months in the HIV-negative cohort compared to 3 (2-6.5) months in the HIV-positive cohort (p ¼ 0.140). Fourteen percent (8 of 59) of the HIV-negative cohort had mupirocin nasal spray prescribed during follow-up compared to 15.0% (9 of 60) in the HIV-positive cohort (p ¼ 0.822).
Discussion
This prospective cohort study evaluated the effects of HIV infection on the S. aureus nasal carriage and CAPDassociated staphylococcal infective outcomes in patients with ESRD who required dialysis. HIV infection was associated with significantly higher MRSA nasal carriage and staphylococcal peritonitis rates, and HIV-positive patients with CD4 count !350 cells/mL had significantly higher S. aureus nasal colonization rates. However, our study failed to demonstrate any significant differences with respect to catheter infection rates in relation to HIV infection. CD4þ cell count <200 cells/ mL in the HIV-positive cohort and S. aureus nasal carriage, were found to independently predict S. aureus peritonitis.
The difference between the HIV-positive cohort and HIV-negative cohort in relation to the S. aureus nasal carriage rate was not statistically significant, but HIVpositive patients with baseline CD4þ count !350 cells/ mL were associated with significantly higher S. aureus nasal colonization compared to the HIV-negative cohort. Furthermore, HIV and baseline CD4þ cell counts were found to independently predict the detection of nasal S. aureus in our multivariable logistic regression model, and S. aureus nasal carriage was detected significantly earlier during follow-up in the HIV-positive cohort compared to the HIV-negative cohort. S. aureus nasal colonization rates were lower in the HIV-positive patients with CD4þ counts <350 cells/mL compared to those with CD4þ counts !350 cells/mL. This observation may have been influenced by the increased dropout rate in the HIV-positive cohort attributed to death, which predominantly affected the HIV-positive subgroup with CD4þ counts <350. The decreased observation times may have undermined the detection of S. aureus in this subgroup compared to longer observation times among those with higher CD4þ counts and those in the HIV-negative cohort. These results suggest an association of HIV with S. aureus nasal colonization that may be better defined in a larger more adequately powered study.
The MRSA nasal carriage rate in the HIV-positive cohort was significantly higher than that in the HIVnegative cohort, and that it was much higher than the pooled MRSA nasal carriage rate estimate of 6.9% (95% CI 4.8-9.3) reported in a meta-analysis of HIV-positive non-CAPD populations [16] . Furthermore, HIV positive status and baseline CD4þ cell count were significant factors associated with MRSA nasal colonization on both univariate and multivariable logistic regression analysis. These significant relations highlight the increased risk of MRSA colonies in the nares associated with HIV infection, which raises concerns about the subsequent development of more serious MRSA infections. Furthermore, the significantly higher proportion of episodes of methicillin-sensitive S. aureus peritonitis in the HIV-negative cohort than in the HIV-positive cohort highlights the relatively low burden of methicillin-resistant infections in the HIV-negative group. Infection with HIV has been positively linked to an increased risk of MRSA colonization and subsequent infection in the general population [17] [18] [19] . Colonization and infection by MRSA, which is commonly acquired through nosocomial contact, have been associated with exposure to antibiotics, prior hospitalization, illicit drug use, chronic skin disease, and risky lifestyle behaviors in the general population [18, 20] . Healthcare-and antibiotic-associated exposures may have increased the risk of MRSA colonization in our HIV-positive CAPD cohort; however, these variables were not directly measured or controlled for in our study design. The community-associated acquisition could also have contributed to the earlier detection of MRSA colonization in our HIV-positive cohort, as compared to the later detection of MRSA colonization in the HIV-negative cohort, suggesting a more traditional nosocomial-associated acquisition in the HIV-negative cohort [21] .
The HIV-positive cohort had a higher staphylococcal peritonitis rate than the HIV-negative cohort, because of the significantly increased CNS peritonitis incidence in the former compared with that in the latter, which highlights the increased vulnerability of HIV-positive patients to touch contamination. Coagulase-negative staphylococci is a common skin commensal found in many parts of the body (nose, axilla, groin, etc.) to various degrees [22, 23] . It is also the most commonly isolated pathogen causing peritonitis in patients on CAPD [24] . Factors associated with the development of CNS peritonitis are access to the peritoneum via the catheter, bacterial characteristics allowing evasion of host defenses, immune depression induced by conventional PD fluids, and inherent host immune system dysfunction [22, 25, 26] . In this study, HIV was found to increase the risk of developing CNS peritonitis, reflecting the immunosuppressive state of HIV and the resultant impaired ability of local peritoneal immune defense mechanisms to combat the contaminating CNS organisms. Furthermore, CNS nasal carriage was found to be significantly increased in the HIV-negative cohort compared to that in the HIV-positive cohort, suggesting HIV-associated changes to the typical body commensal patterns favoring organisms such as MRSA, which are associated with greater healthcare exposure. However, CNS nasal carriage was not significantly associated with CNS peritonitis. Previous reports have also shown a disconnect between CNS strains colonizing the body and those causing infection, as peritonitis-cultured strains tended to differ from those isolated from other body sites before infection [22, 23] .
On multivariable analysis, HIV and diabetes were prominent independent predictors for the development of staphylococcal peritonitis, reinforcing the suggested risks attributed to impaired immunity. Furthermore, HIV and BMI were prominent independent predictors for the development of CNS peritonitis. BMI was found to be a protective predictor for this type of peritonitis. A result also reported by another South African study by Isla et al. [27] where BMI was protective for all-cause peritonitis. These results may suggest a nutritional protective effect, in contrast to some peritonitis publications that have reported an increased peritonitis risk associated with higher BMI [28] [29] [30] . This adverse risk associated with lower BMI probably reflects increased hazards due to undernutrition and the resultant immunocompromise hindering effective containment of advancing CNS organisms contaminating the CAPD system. Both these South African studies were likely influenced by a national rationing policy favoring ESRD patients with lower BMI levels (<35 kg/m 2 ) for access to scarce renal replacement therapy, thus limiting the ability to detect possible hazards associated with obesity [31] . The S. aureus peritonitis rate was not affected by HIV infection status, as reflected by similar peritonitis rates between the two cohorts. However, HIV-positive patients with CD4þ counts <200 cells/mL were noted to have a six-fold higher S. aureus peritonitis rate compared to the HIV-negative cohort. Moreover, this HIVpositive sub-group was associated with increased hazards for developing S. aureus peritonitis events both on univariate and multivariable Cox proportional hazard models suggesting a peritonitis risk profile influenced by changes in immunological state and likely resulting from impaired local immunity [25] . Further, on multivariable analysis, diabetes and S. aureus nasal carriage were found to be other independent predictors of S. aureus peritonitis. These associations support a role for decreased immunity and S. aureus nasal carriage in the risk profile for S. aureus peritonitis.
Compared with the HIV-negative state, HIV infection was associated with higher S. aureus and all-cause catheter infection rates. However, these differences were not statistically significant, which was probably a consequence of the lower numbers of these outcomes. The study's protocol did not restrict the use of mupirocin prophylaxis, either at the exit sites or the nares for ethical reasons, because these prophylactic measures significantly reduce S. aureus-associated catheter infections [32] . However, mupirocin was not uniformly used by treating physicians. Concerns of resistance led to mupirocin being withdrawn from use in general CAPD by the hospital's therapeutics committee midway through the study period, thereafter reserved for nasal decolonization of S. aureus. Nevertheless, the sporadic use of mupirocin likely suppressed the incidence of exit site and tunnel infections.
The main limitation of our study is that it was a single-center observational study, which limits the causation inferences that can be drawn. The sample size may have been too small for differences in the S. aureus nasal colonization and catheter infection outcomes to be fully appreciated and may have led to wide confidence intervals in some observed associations. The reported outcomes were secondary outcomes in the parent study and were not the primary determinants of the sample size calculations. Furthermore, the disproportionately higher mortality rate in the HIV-positive cohort contributed to a significantly higher dropout rate and a significantly shorter observation time compared to the HIV-negative cohort. This observation-time bias may have resulted in an underestimation of S. aureus nasal colonization and peritonitis, and catheter-associated infection rates in the HIV-positive cohort. However, it is not expected to have meaningfully altered observed associations, such as the CNS peritonitis risk associated with HIV, as this kind of potential bias is likely to have led to an underestimation of observed associations rather than enhance them. The differences in the S. aureus nasal colonization and infection rates require further investigation with additional research in prophylactic measures. This study's findings suggest that HIV infection adversely influences MRSA nasal colonization and that it may increase the risk of CNS peritonitis. Differences in the S. aureus peritonitis and catheter infection rates in relation to HIV infection were not significant. However, S. aureus nasal carriage and a CD4þ cell count <200 cells/mL associated with HIV were shown to adversely influence the risk for S. aureus peritonitis. These observations contribute to our understanding of the resistance profiles of S. aureus colonizers and the staphylococcal organism patterns that are likely to cause infection, which may assist in guiding appropriate antibiotic therapy and prophylaxis.
